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Abstract Novel methods and associated tools permitting
individual identification in publicly accessible SNP data-
bases have become a debatable issue. There is growing
concern that current technical and ethical safeguards to
protect the identities of donors could be insufficient. In the
context of human embryonic stem cell research, there are
no studies focusing on the probability that an hESC line
donor could be identified by analyzing published SNP
profiles and associated genotypic and phenotypic informa-
tion. We present the International Stem Cell Forum (ISCF)
Ethics Working Party’s Policy Statement on “Publishing
SNP Genotypes of Human Embryonic Stem Cell Lines
(hESC)”. The Statement prospectively addresses issues
surrounding the publication of genotypic data and associ-
ated annotations of hESC lines in open access databases. It
proposes a balanced approach between the goals of open
science and data sharing with the respect for fundamental
bioethical principles (autonomy, privacy, beneficence, jus-
tice and research merit and integrity).
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The International Stem Cell Initiative (ISCI) [1]—launched
under the auspices of the International Stem Cell Forum
(ISCF) [2]—is a worldwide collaborative effort to establish
basic criteria and techniques to underpin the development
of applications for hESC in human medicine. The Initiative
has collected comprehensive background information on
individual cell lines (e. g. derivation and maintenance
conditions) in order to systematically study hESC in an
effort to establish international standards for characterization.
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Registry [3]. It is used as a reference in other stem cell
registries such as the European hESCreg.
The ISCI is characterizing genotypically different hESC
lines isolates using high density Illumina BeadArrays to
interrogate the samples for a range of genomic features. The
particular BeadArray chosen is the HUMAN 1M-DUO v3.
The 1M-DUO array provides a very high coverage of
genome markers in general and in particular single
nucleotide polymophisms (SNP’s). This high density
coverage means that very detailed information about a cell
line’s genotype will be gathered, and by implication also
about the donors of the gametes or of other cells that gave
rise to the cell lines.
In contrast to the genotype of cell lines derived from a
single donor, the genotype of a hES cell does not
correspond directly to the genotype of the individuals who
donated the embryo from which the hES cell line was
derived. There is effectively no possibility of donor
identification based solely upon the genotype of a hESC
line, and hence, the genotype of the embryo from which it
was derived. Nevertheless, it may still be possible to infer
some genomic information about the gamete donors. Under
remote circumstances and solely when additional informa-
tion is available regarding the donation (e.g. date, place of
embryo donation together with information about the
genotype of the donor) might it be possible to identify a
donor.
For the immediate purposes of the ISCI study, it is not
necessary to identify the genotypes of individual cell lines,
but rather to present conclusions derived from aggregating
the individual data. However, upon completion of the
project, the International Stem Cell Initiative (ISCI) will be
in possession of scientifically useful information about the
genotypes of the individual cell lines which could be
published in the scientific literature and may be lodged in
the ISCI Human ES Cell Registry.
Novel methods and associated tools—such as the ones
described above -permitting individual identification in
publicly accessible SNP databases have become a debatable
issue [4, 5]. There is concern that established safeguards to
protect the identities of donors could be insufficient [6]. In
the context of stem cell research, however, there are no
studies focusing on the probability that similar methods and
tools could be used to identify a hES cell line donor by
analyzing published SNP profiles and associated phenotypic
information.
It is the sense of the EWP that the likelihood of revealing
donor identity is remote. While revealing donor identity is
improbable, potential donors should be made aware that
genotypic data may be in the public domain. However, in
an area of research moving toward therapies and where
donors of embryos provided hES cells under conditions of
anonymity, a proportional approach to privacy requires
examining the probability of identifiability as well as the
balancing of risks and benefits. As stated by the Data
Protection Working Party of the European Commission,
Opinion 4/2007:
“... a mere hypothetical possibility to single out the
individual is not enough to consider the person as
“identifiable”. If, taking into account “all the means
likely reasonably to be used either by the controller or
by any other person” that possibility does not exist or
is negligible, the person should not be considered as
“identifiable” and the information would not be
considered as “personal data” [7].
Thus, it is the view of the EWP that already existing
hESC lines should be placed in open access databases if in
the opinion of their curator there is no reason to believe that
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Stem Cell Rev and Rep (2011) 7:482–484 483such data should not be made public, and that their
publication complies with both the donor’s original in-
formed consent and with national regulations.
The overall aim of the International Stem Cell Forum is
to promote global good practices through collaboration in
stem cell research. While recognizing ethical and legal
constraints, the ISCF supports the sharing of data with the
international community to accelerate progress in this
vitally important area of biomedical science. The ISCF is
respectful of the privacy of the individuals who contribute
to the advancement of the field via the donation of their
biological materials. To achieve these aims, while respect-
ing fundamental bioethical principles such as beneficence,
justice and research merit and integrity, the ISCF EWP
recommends the following policy:
ISCF Ethics Working Party Policy Statement
The goal of open science and the principle of transparency
argue in favour of maintaining open access databases, even
when faced with scenarios of possible—yet extremely
unlikely—identification of donors. In the future, all
genotypic data and associated annotations arising from the
International Stem Cell Initiative (ISCI) should be orga-
nized and placed in an Open Access Database. Thus, the
ISCF EWP encourages the scientific community to pro-
spectively adopt appropriate b r o a di n f o r m e dc o n s e n t
protocols to govern future stem cell research involving
genotypic information. To that end, such consent should
foresee genotypic data eventually being placed in open
access databases. Where possible, it should prospectively
seek explicit consent for donor SNP data to be published
in open access databases on the internet. However for
already existing lines, we also endorse open access
databases where there is no re a s o nt ob e l i e v et h a ts u c h
publication would contravene donor consent or applicable
laws.
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